Available 24/7 for Urgent On-Site or Virtual Consulting
Modern drug manufacturing relies on the accuracy and reliability of digital and manual records. This guide explores how to prepare for FDA data integrity inspections in 2026. We cover ALCOA+ principles, audit trail reviews, and system validation. Learn to identify vulnerabilities in your data lifecycle and implement corrective actions to ensure total compliance and patient safety.
Managing food safety requires a deep understanding of current regulatory trends. This guide analyzes the most frequent FDA food facility inspection observations related to preventive controls. From hazard analysis failures to sanitation gaps, we break down what recent reports reveal about industry non-compliance. Learn actionable steps to strengthen your food safety plan and ensure audit readiness.
Handling FDA 483 observations on sterility and potency requires a precise technical response. This guide explores how Pharmaceutical QA teams can address regulatory findings, implement robust CAPA systems, and ensure long-term CGMP compliance. Learn to navigate complex inspections while maintaining high manufacturing standards for sterile injectable and high-potency drug products.
Modern pharmaceutical supply chains face new pressures from evolving regulatory standards. This article explores how recent FDA drug facility inspection findings impact global compliance strategies. We analyze data integrity, quality management maturity, and risk mitigation. Learn how manufacturers can adapt to these changes to ensure uninterrupted market access and patient safety.
Navigating an FDA export detention or import alert can be a nightmare for food importers. This detailed guide outlines essential post-inspection action plans to resolve compliance issues, manage regulatory risks, and restore your supply chain. Learn how to address 483 observations, implement corrective actions, and work toward a successful removal from the FDA Import Alert list effectively.
Stay ahead of regulatory shifts with our deep dive into FDA pharmaceutical CGMP inspection trends from 2025-2026. This comprehensive guide analyzes recent warning letters to reveal common pitfalls in data integrity, CAPA systems, and manufacturing controls. Learn how to strengthen your quality management system and ensure audit readiness in an increasingly digitized regulatory landscape.
Preparing for an FDA QMSR inspection program audit requires a deep understanding of the new regulatory landscape. This 2026 guide covers everything from rule interpretation to the best tools for medtech compliance. Ensure your quality management system is ready for the transition from QSR to QMSR by identifying common challenges and implementing best practices for medical device audits.
Identifying and closing inspection program gaps is critical for medical device manufacturers transitioning to the FDA’s Quality Management System Regulation (QMSR). This comprehensive guide explores technical strategies, risk-based methodologies, and best practices to ensure your internal audits align with ISO 13485:2016 and FDA expectations, preventing 483 observations and warning letters.
As the MedTech industry transitions from QSR to QMSR, manufacturers face significant operational hurdles. This guide explores the most common QMSR inspection challenges, focusing on risk management integration, ISO 13485 alignment, and data integrity. Learn how to identify systemic gaps and implement proactive solutions to ensure your quality management system remains compliant in 2026.
The transition to the FDA’s Quality Management System Regulation (QMSR) requires a new approach to compliance. This comprehensive guide explores the QMSR Medical Device Regulation Inspection Guidance document. Discover how the harmonization with ISO 13485:2016 impacts your audit strategy, risk management, and overall regulatory standing. Learn actionable steps to ensure your medical device QMS is ready for federal investigators in 2026.